Immunological mechanism underlying the immune response to recombinant human protein therapeutics.

Recombinant human (rhu) protein therapeutics are powerful tools to treat several severe diseases such as multiple sclerosis and diabetes mellitus, among others. A major drawback of these proteins is the production of anti-drug antibodies (ADAs). In some cases, these ADAs have neutralizing capacity and can interfere with the efficacy and safety of the drug. Little is known about the immunological mechanisms underlying the unwanted immune response against human homolog protein therapeutics. This article aims to provide current insights into recent immunological developments and to link this with regard to production of ADAs. A particular focus is given to aggregates being present in a rhu protein formulation and their impact on the immune system, subsequently leading to breakage of tolerance and formation of ADAs. Aggregation is one of the key factors in immunogenicity and by reducing aggregation one can reduce immunogenicity and make drugs safer and more efficient.

[1]  J. Weill,et al.  Human marginal zone B cells. , 2009, Annual review of immunology.

[2]  P. Stadler,et al.  HLA-DRB1∗0401 and HLA-DRB1∗0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis , 2008, American Journal of Human Genetics.

[3]  M. Yuseff,et al.  Dynamics of Membrane Trafficking Downstream of B and T Cell Receptor Engagement: Impact on Immune Synapses , 2009, Traffic.

[4]  A. Jegerlehner,et al.  Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. , 2008, Current topics in microbiology and immunology.

[5]  A. Trad,et al.  Thymus-independent type 2 antigen induces a long-term IgG-related network memory. , 2008, Molecular immunology.

[6]  Philippos K. Tsourkas,et al.  Mechanisms of B-cell synapse formation predicted by Monte Carlo simulation. , 2006, Biophysical journal.

[7]  A. Ross,et al.  Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout. , 2009, Journal of pharmaceutical sciences.

[8]  N. Gao,et al.  Requirements for the natural killer cell-mediated induction of IgG1 and IgG2a expression in B lymphocytes. , 2008, International immunology.

[9]  A. Lanzavecchia,et al.  Toll‐like receptor stimulation as a third signal required for activation of human naive B cells , 2006, European journal of immunology.

[10]  I. Macdougall.  Epoetin-induced pure red cell aplasia: diagnosis and treatment , 2007, Current opinion in nephrology and hypertension.

[11]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[12]  H. Spits,et al.  T cell–independent development and induction of somatic hypermutation in human IgM+IgD+CD27+ B cells , 2008, The Journal of experimental medicine.

[13]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[14]  C. Snapper,et al.  T cell independent antigens. , 1995, Current opinion in immunology.

[15]  C. Snapper,et al.  B‐cell activation by T‐cell‐independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms , 2000, Immunological reviews.

[16]  S. O’Rahilly,et al.  Severe insulin resistance due to anti‐insulin antibodies: response to plasma exchange and immunosuppressive therapy , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[17]  W. Jiskoot,et al.  Erythropoietin-Associated PRCA: Still an Unsolved Mystery , 2006, Journal of immunotoxicology.

[18]  I. Meyts,et al.  Human Memory B Lymphocyte Subsets Fulfill Distinct Roles in the Anti-Polysaccharide and Anti-Protein Immune Response1 , 2008, The Journal of Immunology.

[19]  M. Krumbholz,et al.  Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. , 2008, Brain : a journal of neurology.

[20]  Masanori Onda,et al.  Reducing the immunogenicity of protein therapeutics. , 2009, Current drug targets.

[21]  J. Oger,et al.  The IgG subclass-specificities of anti-IFNβ antibodies change with time and differ between the IFNβ products in relapsing remitting multiple sclerosis patients , 2007, Journal of Neuroimmunology.

[22]  Paolo Gallo,et al.  Immunogenicity of interferon beta: differences among products , 2004, Journal of Neurology.

[23]  Miriam Merad,et al.  Dendritic cell homeostasis. , 2009, Blood.

[24]  Huub Schellekens,et al.  Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  M. Brendel,et al.  Binding characteristics and crossreactivity of insulin autoantibodies and insulin antibodies directed to three different insulin molecules , 2008, Acta Diabetologica.

[26]  Huub Schellekens,et al.  Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity? , 2003, Pharmaceutical Research.

[27]  S. Valitutti.  Immunological synapse: center of attention again. , 2008, Immunity.

[28]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[29]  R. Musso.  Efficacy and safety of recombinant factor VIII products in patients with hemophilia A. , 2008, Drugs of today.

[30]  E. Renard,et al.  Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control , 2009, Diabetes/metabolism research and reviews.

[31]  W. Jiskoot,et al.  Eprex-associated pure red cell aplasia and leachates , 2006, Nature Biotechnology.

[32]  B. Hurwitz.  Important sources of variability in clinical studies of neutralizing antibodies against interferon beta , 2008, Journal of the Neurological Sciences.

[33]  Huub Schellekens,et al.  Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of Pharmacy and Science.

[34]  Allen R Nissenson,et al.  Pure red-cell aplasia and epoetin therapy. , 2004, The New England journal of medicine.

[35]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[36]  D. Miller,et al.  Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta , 2008, Multiple sclerosis.

[37]  P. Schneider,et al.  Cracking the BAFF code , 2009, Nature Reviews Immunology.

[38]  W. Jiskoot,et al.  Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta , 2005, Pharmaceutical Research.

[39]  M. Nussenzweig,et al.  T-independent type II immune responses generate memory B cells , 2006, The Journal of experimental medicine.

[40]  William F Weiss,et al.  Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.

[41]  S. Fineberg,et al.  Immunological responses to exogenous insulin. , 2007, Endocrine reviews.

[42]  Huub Schellekens,et al.  Immunogenicity of biopharmaceuticals. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[43]  K. Bendtzen,et al.  Immunogenicity of interferon‐β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration , 2000 .

[44]  N. Kochibe,et al.  Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells. , 1988, The Journal of biological chemistry.

[45]  P. Sørensen,et al.  Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies? , 2008, Multiple sclerosis.

[46]  Antonio Lanzavecchia,et al.  Dendritic cell migration to peripheral lymph nodes. , 2009, Handbook of experimental pharmacology.

[47]  R. Peces,et al.  Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. , 1996, The New England journal of medicine.

[48]  Adrian Whitty,et al.  Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β) , 1998, Pharmaceutical Research.

[49]  S. Tangye,et al.  Memory B cells: Effectors of long‐lived immune responses , 2009, European journal of immunology.

[50]  C. Snapper,et al.  A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. , 1996, Journal of immunology.